You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1598 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    ceritinib - Second-line monotherapy of ALK-positive locally advanced (not amenable to curative therapy) or metastatic NSCLC, in patients who have experienced disease progression or intolerance to crizotinib, according to specific criteria
Nov 2024
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Lymphocytic (CLL)
Intent: Palliative
Funding:
ODB - General Benefit
    chlorambucil
Nov 2024
Regimen
Regimen
Cancer Type:
Skin, 
Squamous Cell
Intent: Palliative
Jul 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Curative, Palliative
May 2019
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
May 2019
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Apr 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Gynecologic, 
Germ Cell
Intent: Adjuvant
Dec 2021
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Adjuvant
Nov 2021
Regimen
Cancer Type:
Gynecologic, 
Vulva
Intent: Neoadjuvant, Palliative
Oct 2017
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - In Combination with Pomalidomide and Dexamethasone for Previously Treated Multiple Myeloma
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    pomalidomide - In combination with bortezomib and dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma, based on criteria
Apr 2025

Pages